

# Impact of Omalizumab Treatment on Asthma-Related Health Care Resource Utilization in a Real-world Data Set From a Managed Care Plan

Lane Higley,<sup>1</sup> Yamina Rajput,<sup>2</sup> Joseph Dang,<sup>2</sup> James Parker,<sup>1</sup> Elisha Delong Sieg,<sup>2</sup> Eunice Chang,<sup>3</sup> Sheila Reiss Reddy,<sup>3</sup> Matthew Mitchell<sup>1</sup>

<sup>1</sup>SelectHealth, Salt Lake City, UT, USA; <sup>2</sup>Genentech, Inc., South San Francisco, CA, USA; <sup>3</sup>Partnership for Health Analytic Research, LLC, Beverly Hills, CA, USA

## Background

- Asthma accounted for ~189,00 hospital inpatient stays, 1.8 million emergency department (ED) visits, and 9.8 million physician office visits in 2016.<sup>1</sup>
- An important goal of asthma management is to reduce asthma exacerbations.<sup>2,3</sup>
- In clinical studies, treatment with asthma biologics has been associated with reductions in asthma exacerbations; however, further understanding of the impact of biologic treatment on asthma-related hospitalizations and other health care resource utilization (HCRU) in a real-world setting is required.<sup>4,5</sup>
- Omalizumab is an anti-immunoglobulin E monoclonal antibody that is effective at reducing asthma exacerbations and improving asthma control in patients with moderate-to-severe persistent allergic asthma that is inadequately controlled with inhaled corticosteroids.<sup>5</sup>

## Objective

- To examine the asthma-related HCRU among patients treated with omalizumab for asthma in an integrated regional managed care plan.

## Methods

### Patients

- A retrospective cohort study using medical and prescription claims data from the SelectHealth insurance plan from January 2012 to December 2016 was conducted.
- Eligible patients were identified in January 2013 to December 2015.
- Inclusion criteria:
  - Aged ≥6 years **and**
  - Had ≥2 medical claims occurring on different dates with a primary diagnosis of asthma **and**
  - Had appropriate enrollment records **and**
  - Treated with omalizumab for ≥16 weeks (without a gap of >4 weeks) **and**
  - Had ≥90 days of follow-up after the index date (post-index period), defined as the date that the minimum exposure to omalizumab had been met (index date).

### Assessments

- Annualized asthma-related HCRU, defined as medical claims with a primary diagnosis of asthma, was assessed during the pre- and post-index periods. Asthma-related HCRU included:
  - Number of hospitalizations
  - Total days of inpatient hospital stays
  - Number of ED visits.
- Annualized asthma-related HCRU was calculated as the proportion of hospitalizations or visits over the entire follow-up, divided by years of follow-up.

### Statistical Analysis


- Descriptive statistics were used for baseline demographic and clinical characteristics.
- Means and SDs for annualized asthma-related HCRU were summarized in the pre- and post-index periods.

## Results

### Patient Disposition and Baseline Characteristics

- Of the 194 patients treated with omalizumab between 2013 and 2015, 102 patients met the study criteria (**Figure 1**).
- The mean (SD) patient age was 45.2 (17.0) years, and the majority of patients were female (64.7%; **Table 1**).
- The most common comorbidities were rhinitis (91.2%), sinusitis (61.8%), and cough (49.0%; **Table 2**).

**Figure 1. Study Cohort Selection**



ID, identification period. \*The index date is the date that the minimum exposure of omalizumab (16 weeks or 90 days of use) was met.

**Table 1. Baseline Demographic and Clinical Characteristics**

Characteristic	Omalizumab N=102
Mean (SD) age, y	45.2 (17.0)
Female, n (%)	66 (64.7)
Mean (SD) Charlson Comorbidity Index score	1.5 (1.0)
State, n (%)	
Idaho	8 (7.8)
Utah	94 (92.2)


**Table 2. Patient Baseline Comorbidities Among Omalizumab Users (≤1 Year Before Index Date)**

Comorbidity, n (%)	Omalizumab N=102
Rhinitis	93 (91.2)
Sinusitis	63 (61.8)
Cough	50 (49.0)
Gastroesophageal reflux disease	31 (30.4)
Acute upper respiratory infection	31 (30.4)
Conjunctivitis	31 (30.4)
Eczema/dermatitis	25 (24.5)
Urticaria/angioedema	21 (20.6)
Food allergy	16 (15.7)
Atopic dermatitis and related conditions	12 (11.8)
Nasal polyposis	12 (11.8)
Anaphylaxis	9 (8.8)
Chronic obstructive pulmonary disease	9 (8.8)
Tonsillitis	1 (1.0)
Chronic otitis media	1 (1.0)

### Pre- and Post-index Period Asthma-Related HCRU

- Asthma-related HCRU decreased from the pre- to post-index periods.
- The mean (SD) number of annual asthma-related hospitalizations decreased from 0.08 (0.52) to 0.01 (0.07; **Figure 2**), while the mean total days of inpatient hospital stays annually decreased from 0.26 (1.95) to 0.03 (0.22; **Figure 3**). The mean (SD) number of annual asthma-related ED visits decreased from 0.20 (0.86) to 0.09 (0.35; **Figure 4**).
- To place these results in context, in a health plan enrolling 100 patients diagnosed with asthma, the total number of asthma-related hospitalizations would decrease from ~8 admissions to 1 admission per year following omalizumab use.

**Figure 2. Annualized No. of Hospitalizations**




**References** 1. Centers for Disease Control and Prevention. Most recent national asthma data. [https://www.cdc.gov/asthma/most\\_recent\\_national\\_asthma\\_data.htm](https://www.cdc.gov/asthma/most_recent_national_asthma_data.htm). Accessed August 20, 2019. 2. National Asthma Education and Prevention Program. *J Allergy Clin Immunol*. 2007;120(5)(suppl):S94–138. 3. Global Initiative for Asthma. Global strategy for asthma management and prevention. <https://ginasthma.org/gina-reports/>. Accessed August 20, 2019. 4. Farne HA, et al. *Cochrane Database Syst Rev*. 2017;9:CD010834. 5. Normansell R, et al. *Cochrane Database Syst Rev*. 2014;(1):CD003559. 6. Casale TB, et al. *J Allergy Clin Immunol Pract*. 2019;7:156–64.e1. 7. Ke X, et al. *Clin Ther*. 2018;40:1140–58.e4.


**Disclosures** LH, JP, MM: employee of SelectHealth. YR, JD, EDS: employees of Genentech, Inc. EC, SRR: employees of Partnership for Health Analytic Research, LLC, a health services research company paid by Genentech, Inc. to conduct this research.

**Acknowledgments** This analysis was funded by Genentech, Inc., a member of the Roche Group, and Novartis Pharma AG. Third-party graphics and editorial support was provided by Envision Pharma Inc., and funded by Genentech, Inc., a member of the Roche Group, and Novartis Pharmaceuticals Corporation.

**Figure 3. Annualized Mean Duration of Inpatient Hospital Stays**



**Figure 4. Annualized Number of ED Visits**



ED, emergency department.

- Safety was not evaluated in this analysis.

## Conclusions

- In this real-world analysis of patients enrolled in an integrated regional managed care plan, asthma-related HCRU (hospitalizations, days of inpatient hospital stays, and ED visits) was lower during the post-index period for patients with asthma treated with omalizumab.
- To place the reductions in HCRU observed in context, in a health plan enrolling 100 patients diagnosed with asthma, the total number of asthma-related hospitalizations would decrease from ~8 admissions to 1 admission per year following omalizumab use.
- Limitations of the study comprised of missing or incomplete enrollment records, which limited the number of patients included in the study.
- Nonetheless, these observations are consistent with prior real-world studies assessing the impact of omalizumab on HCRU.<sup>6,7</sup>



<http://poster.posterslab.com/AMCP2019-Nexus/>